UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Terry Matkovits – Chief Development Officer Terry Ferguson – Chief Medical Officer Keith Kucinski – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Operator Greetings and welcome to the Matinas BioPharma First Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a remin ...

May 10, 2023 BIOPHARMA www.matinasbiopharma.com NYSE American: MTNB Lipid Nanocrystals™ (LNCs) 3 Matinas Has Developed Two Distinct Platforms for Delivering Therapeutic Cargo Phosphatidylserine and its Unique Properties Link Both Platforms 4 Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Stable, phospholipidcalcium crystalline nanocrystals Extra-hepatic targeting • Validated Blood-Brain-Barrier penetration (MAT2203) Safe & stable • No evidence of immunogenicity or cytotoxi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Matkovits - Chief Development Officer Conference Call Participants Greg Fraser - Truist Securities Operator Greetings and welcome to the Matinas BioPharma 2022 Fourth Quarter and Full Year Conference Call. [Operator Instructions] As a reminder, this conference is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdicti ...

Financial Data and Key Metrics Changes - The company reported a net loss attributable to common shareholders of approximately $5.5 million or $0.03 per share for Q3 2022, compared to a net loss of $6.8 million or $0.03 per share for the same period in 2021, indicating a reduction in loss [19] - Cash, cash equivalents, and marketable securities at September 30, 2022, were approximately $33.1 million, down from $49.6 million at December 31, 2021, but the company believes this is sufficient to fund operations through 2023 [19] Business Line Data and Key Metrics Changes - The company achieved significant milestones in its MAT2203 program, particularly in the Phase 2 EnACT trial for cryptococcal meningitis, which demonstrated unprecedented survival rates exceeding 90% [9][10] - MAT2203 is positioned for global development and registration, with the European Medicines Agency granting orphan drug designation for the treatment of cryptococcosis [10] Market Data and Key Metrics Changes - The World Health Organization highlighted the rising threat of invasive fungal diseases, particularly among immunocompromised populations, which aligns with the company's focus on developing MAT2203 [10] - The WHO's fungal priority pathogens list includes cryptococcal meningitis and aspergillosis as critical threats, indicating a growing market need for effective treatments [10] Company Strategy and Development Direction - The company plans to initiate a Phase 3 trial for MAT2203 in cryptococcal meningitis in Q1 2023, expanding clinical sites and potentially adding patients to offset unforeseen deaths [15] - The strategy includes securing multiple orphan indications for MAT2203 and maximizing regulatory exclusivities while exploring broader applications for the treatment of invasive fungal infections [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the MAT2203 program's potential, citing strong clinical data and positive feedback from key opinion leaders [10][28] - The company is focused on maintaining a strong cash position and exploring non-dilutive financing options to support its development efforts [21] Other Important Information - The company is actively engaged in licensing discussions with BioNTech regarding the oral delivery of nucleic acids, which is seen as a significant opportunity [20] - The company has expanded its intellectual property portfolio surrounding the LNC platform with multiple new provisional patent filings [22] Q&A Session Summary Question: Can you expand on the feedback from doctors at ID Week regarding MAT2203? - Management noted that survival and safety were key elements that resonated with physicians, highlighting the unprecedented survival rates and safety profile of MAT2203 [26][28] Question: Will the Phase 3 study for invasive fungal infections enroll patients with different infections? - The company plans to enroll patients suffering from various invasive fungal infections, focusing on mucor and aspergillosis, and aims for a streamlined basket study design [30][31] Question: What is the standard treatment protocol with amphotericin for mucor and aspergillosis? - Typically, IV amphotericin is restricted to one to two weeks of treatment due to associated toxicities, followed by step-down therapy with azoles or echinocandins [36] Question: Can you provide details on the harmonization of the EU Phase 3? - Early feedback from the European Medicines Agency was incorporated into the protocol planning for the Phase 3 study, ensuring alignment with regulatory requirements [38] Question: What is the status of the BioNTech collaboration? - Discussions with BioNTech are ongoing, with both parties recognizing the potential value of the collaboration, although specific hurdles remain to be addressed [43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...

MATINAS BIOPHARMA Corporate Presentation September 2022 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Representative Jerry Jabbour - Chief Executive Officer Dr. Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer Dr. Raphael Mannino - Chief Scientific Officer Dr. Terry Ferguson - Chief Medical Officer Thomas Hoover - Chief Business Officer Conference Call Participants Bert Hazlett - BTIG Operator Hello. And welcome to ...